Tech Company Inital Public Offerings
Adagene IPO
On 2/11/2021, Adagene went public.
Transaction Overview
Company Name
Announced On
2/11/2021
Transaction Type
IPO
Amount
$140,000,000
Proceeds Purpose
We intend to use the net proceeds from this offering for the following purposes: approximately 95% for research and development; approximately 26% to fund ADG106, covering both Phase I trial and advancement to Phase II trial; approximately 26% to fund both ADG126 and ADG116, covering Phase I trial and advancement to Phase II trial; approximately 43% for our technical and platform development and development of our preclinical candidates; and approximately 5% for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
315 Montgomery St.
San Francisco, CA 94104
USA
San Francisco, CA 94104
USA
Phone
Undisclosed
Website
Email Address
Overview
Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Luo
Chief Financial Officer
Raymond Tam
Chief Scientific Officer
Felix Du
Vice President
Yan Li
VP - Bus. Development
Alexander Goergen
VP - Operations
Kristine She
Browse more venture capital transactions:
Prev: 2/11/2021: WireWheel venture capital transaction
Next: 2/11/2021: Labster venture capital transaction
Share this article
News on VC Transactions
We record every notable VC transaction. All VC database entries reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs